Tianjin Ringpu Bio-Technology Co.,Ltd.

SZSE:300119 Stock Report

Market Cap: CN¥8.5b

Tianjin Ringpu Bio-TechnologyLtd Past Earnings Performance

Past criteria checks 2/6

Tianjin Ringpu Bio-TechnologyLtd has been growing earnings at an average annual rate of 11%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.9% per year. Tianjin Ringpu Bio-TechnologyLtd's return on equity is 9.7%, and it has net margins of 17.6%.

Key information

11.0%

Earnings growth rate

6.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate7.9%
Return on equity9.7%
Net Margin17.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Nov 05
Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Recent updates

There's No Escaping Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Muted Earnings Despite A 29% Share Price Rise

Nov 26
There's No Escaping Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Muted Earnings Despite A 29% Share Price Rise

Is There An Opportunity With Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) 42% Undervaluation?

Nov 25
Is There An Opportunity With Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) 42% Undervaluation?

Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Nov 05
Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well

Oct 30
These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well

The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More

Oct 08
The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More

Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 26
Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet

Aug 23
Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet

Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly

Jun 26
Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly

Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Apr 05
Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity

Mar 28
Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity

Revenue & Expenses Breakdown

How Tianjin Ringpu Bio-TechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:300119 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,409424582183
30 Jun 242,354434564179
31 Mar 242,339460563177
31 Dec 232,249453555172
30 Sep 232,195387548182
30 Jun 232,170385531160
31 Mar 232,136355518143
01 Jan 232,084347507132
30 Sep 221,985354555105
30 Jun 221,875349530113
31 Mar 221,838369511114
01 Jan 222,007413547117
30 Sep 212,038438522124
30 Jun 212,117454548120
31 Mar 212,106441552116
31 Dec 202,000398551111
30 Sep 201,895302549102
30 Jun 201,73725552797
31 Mar 201,61322449594
31 Dec 191,46719444094
30 Sep 191,34615839989
30 Jun 191,26013737384
31 Mar 191,20312437379
31 Dec 181,19011936080
30 Sep 181,17910837181
30 Jun 181,157117301123
31 Mar 181,112112321105
31 Dec 171,04710534385
30 Sep 171,00813634161
30 Jun 179931384020
31 Mar 179881403980
31 Dec 169701333910
30 Sep 169431293570
30 Jun 169051133640
31 Mar 168321083370
31 Dec 157931103340
30 Sep 15690683300
30 Jun 15639433400
31 Mar 15625343460
31 Dec 14585273270
30 Sep 14669953230
30 Jun 146761133040
31 Mar 147221402990
31 Dec 137551523020

Quality Earnings: 300119 has a large one-off gain of CN¥213.6M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300119's current net profit margins (17.6%) are lower than last year (17.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300119's earnings have grown by 11% per year over the past 5 years.

Accelerating Growth: 300119's earnings growth over the past year (9.4%) is below its 5-year average (11% per year).

Earnings vs Industry: 300119 earnings growth over the past year (9.4%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 300119's Return on Equity (9.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:45
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tianjin Ringpu Bio-Technology Co.,Ltd. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jia ChenChangjiang Securities Co. LTD.
Xu Qing LiuChasing Securities
Junhao FanChina International Capital Corporation Limited